Verona Pharma releases Ohtuvayre for COPD treatment in US, strong financials, upcoming milestones.

From Globe Newswire: 2024-08-08 02:00:00

Verona Pharma announces the availability of Ohtuvayre (ensifentrine) in the US for COPD treatment. Patient shipments have begun. The company’s strong balance sheet supports pipeline expansion. Key milestones include IND submission for a fixed-dose combination of ensifentrine and glycopyrrolate and initiation of Phase 2 trial for non-cystic fibrosis bronchiectasis treatment. FDA approved Ohtuvayre in June 2024. Verona Pharma’s cash position at June 30, 2024, was $404.6 million. R&D expenses for the second quarter were $19.4 million, and SG&A expenses were $49.0 million. Net loss for the quarter was $70.8 million. Verona Pharma will host a conference call today to discuss financial results and corporate update.



Read more at Globe Newswire:: Verona Pharma Reports Second Quarter 2024 Financial Results